Compare · NTRA vs YDES
NTRA vs YDES
Side-by-side comparison of Natera Inc. (NTRA) and YD Bio Limited (YDES): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRA and YDES operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $47.61B, about 171.3x YDES ($278.0M).
- Over the past year, NTRA is up 87.2% and YDES is down 76.5% - NTRA leads by 163.6 points.
- NTRA has been more active in the news (8 items in the past 4 weeks vs 3 for YDES).
- NTRA has more recent analyst coverage (25 ratings vs 0 for YDES).
- Company
- Natera Inc.
- YD Bio Limited
- Price
- $330.23+1.87%
- $3.68-11.96%
- Market cap
- $47.61B
- $278.0M
- 1M return
- +3.64%
- +46.91%
- 1Y return
- +87.15%
- -76.46%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 8
- 3
- Recent ratings
- 25
- 0
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest NTRA
- UBS resumed coverage on Natera with a new price target
- Rothschild & Co Redburn initiated coverage on Natera with a new price target
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $5,917,907 worth of shares (18,160 units at $325.88) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 110,859 units (SEC Form 4) to satisfy withholding tax
- CEO AND PRESIDENT Chapman Steven Leonard sold $545,041 worth of shares (1,698 units at $320.99) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 98,199 units (SEC Form 4)
- New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma
- PRESIDENT, CHIEF BUS. OFFICER Fesko John was granted 20,000 shares and sold $2,095,411 worth of shares (6,517 units at $321.53) as part of a pre-agreed trading plan, increasing direct ownership by 7% to 197,257 units (SEC Form 4) (tax liability)
- Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer
- Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™
- CO-FOUNDER Sheena Jonathan sold $1,951,942 worth of shares (6,000 units at $325.32) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 230,464 units (SEC Form 4)
- Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers
Latest YDES
- CEO Shen Ethan Phd bought $67,447 worth of Ordinary Shares (18,378 units at $3.67), increasing direct ownership by 0.16% to 11,242,531 units (SEC Form 4)
- YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026
- YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute
- SEC Form 424B3 filed by YD Bio Limited
- SEC Form 6-K filed by YD Bio Limited
- YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute
- YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research
- YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada
- YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services
- YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations